(Press-News.org) An unprecedented investment by the University of Sydney, Australia will support up to 40 new continuing positions, empowering the world’s most talented emerging researchers to undertake innovative research to address some of the biggest challenges of our time.
A $100 million investment and a cornerstone of the University’s 2032 Strategy, the Sydney Horizon Fellowship scheme is the first of its kind in Australia and among the most generous university fellowships in the world.
“The Sydney Horizon Fellowships are an unprecedented investment for the University in early and mid-career researchers and demonstrate our commitment to deliver research that is a catalyst for innovation and change,” Vice-Chancellor and President, Professor Mark Scott AO said.
“We know if we want to grow innovation we must support our researchers to tackle the greatest challenges for the common good.
"Early career researchers are vital to solving the challenges of the future and building a better world.”
The scheme, which focuses on research in climate change, health and sustainability, is expected to be hugely popular with both local and international researchers.
It offers up to 40 continuing positions, commencing with a five-year research-focused fellowship which includes training and mentoring, a competitive salary and a generous research funding package.
Professor Emma Johnston, Deputy Vice-Chancellor (Research) said she was proud to launch the Sydney Horizon Fellowships, which she believes will be a game-changer for future academic leaders.
“As knowledge and innovation grow, our early and mid-career researchers are the generation we need to unlock the solutions to climate change, health and sustainability challenges.
“Compounding global crises are having a profound impact on all of us and this record funding gives researchers the time and security to develop their big ideas.”
Open to all disciplines, research programs could include the development of novel technologies, biomedical, legal, business, design, policy and political instruments.
The fellowship scheme also upholds the University’s commitment to equity and diversity, aiming to recruit at least 50 percent female-identifying researchers and strongly encouraging applications from Aboriginal and Torres Strait Islander researchers and those with lived experience of disability.
The University of Sydney ranks 28th in the world for research performance and is in the top five universities globally in the QS Sustainability Rankings, covering research, teaching and community engagement.
“We are proud of our success to date in research in climate change, health and sustainability, such as our leadership on the State of the Environment report, our world-leading work in melanoma and innovations in renewable energy storage,” said Professor Johnston.
“The new fellowships will build our capacity to deliver more work of this calibre and impact in the future.”
Some of the University’s areas of interest include the development of new technologies to mitigate climate change; building understanding of the impact of climate on the environment, business, human health and society; drug discovery and the role of technology in promoting health; and policies and strategies to promote sustainability in agriculture, architecture, energy, finance, waste management, water and transportation.
The fellows will be supported to join existing research centres of the University of Sydney and build new networks across schools and faculties while being mentored by some of the top leaders in their field.
The fellowships are part of a suite of initiatives aimed at supporting the next generation of researchers under the University’s 2032 Strategy. Other projects in development include the creation of a graduate research school to better support higher degree research students, new programs to support research commercialisation and translation, and a comprehensive training and development program supporting early-career researchers to thrive in academia.
Applications for the Sydney Horizon Fellowships close Wednesday 5 July 2023, with the fellows commencing in 2024.
-ENDS-
Media enquiries
Michelle Blowes
Media & PR Adviser, University of Sydney
M: +61 478 303 173 | E: michelle.blowes@sydney.edu.au
END
CHICAGO – Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease. However, an important question has remained unanswered: How long should a patient with advanced non-small cell lung cancer (NSCLC), who receives immunotherapy as part of their initial treatment, continue with treatment?
A new retrospective cohort study, published today in JAMA Oncology and presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract ...
About The Study: The findings of this study provide reassurance that for patients with advanced non–small cell lung cancer whose disease is still responding to immune checkpoint inhibitor therapy at two years, stopping therapy and monitoring rather than continuing immunotherapy indefinitely is a reasonable strategy with sustained clinical benefit.
Authors: Lova Sun, M.D., M.S.C.E., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2023.1891)
Editor’s ...
Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study* show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.
80% of patients included in this study presented with FolRα expression levels higher than 25%. The overall response rate among these patients was 43.8% in the dose expansion cohort, with a median duration of response ...
Carbon-based stimuli-responsive nanomaterials are gaining much attention due to their versatility, including disease diagnosis and treatment. They work under endogenous (pH, temperature, enzyme, and redox) or exogenous (temperature, light, magnetic field, ultrasound) stimuli. Carbon-based stimuli-responsive nanomaterials can be used as smart materials with dynamically tunable physicochemical properties in response to changes in internal or external environmental stimuli. Their diverse combinations of nanostructures and molecular designs, as well as functional ...
ABSTRACT: 4008
CHICAGO ― HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive biliary tract cancer (BTC), researchers from The University of Texas MD Anderson Cancer Center reported at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in The Lancet Oncology.
In the first cohort of the global Phase II HERIZON-BTC-01 trial, which included 80 patients with HER2-positive tumors, the confirmed objective response rate (cORR) was 41% with a median duration of response (DOR) of 12.9 months at a median follow-up of 12.4 months. ...
Survival rate beyond 10 years in children with drug-resistant epilepsy (DRE) was highest after cranial epilepsy surgery and lowest when treated only with antiseizure medications, according to a study published in The Lancet Child and Adolescent Health. This large, retrospective study was the first to compare long-term survival in children with DRE among cohorts treated with medications only, vagus nerve stimulation plus medications, and cranial epilepsy surgery plus medications. Results show that risk of early death was reduced by over 80 percent after surgery and by 40 percent after ...
When one thinks of movie reviews, one might see them as harbingers of success or failure at the box office. Some researchers have previously found that both positive and negative reviews correlate to box office revenues, and the effect of negative reviews diminishes over time.
However, researchers at the University of California, Davis, suggest that is not the case.
Researchers analyzed pre-release commentary and opening weekend box office revenue, turning the impact of movie reviews on its head and revealing an unexpected harbinger of failure phenomenon in the movie industry.
The study, ...
Bile duct cancers are uncommon and aggressive types of gastrointestinal cancer. They include cholangiocarcinomas, which can form inside or outside of the liver, as well as cancers of the gallbladder, and are highly likely to cause serious disease or prove fatal.
Bile duct cancers affect the biliary tract, which consists of organs and ducts that make and store bile and release it into the small intestine. They are known as “silent” cancers, because there are usually no symptoms until they reach later stages. Surgery can be effective if bile duct cancer is caught early, ...
June 2, 2023
Contact:
Emily Gowdey-Backus, 978-934-3369 or Emily_GowdeyBackus@uml.edu
Nancy Cicco, 978-934-4944 or Nancy_Cicco@uml.edu
Startups to unveil cutting-edge point-of-care technologies at Boston medtech event
Medtech and life sciences entrepreneurs and investors forging the future of health care will come together Tuesday, June 6, to showcase pioneering technologies and grow the region’s medtech ecosystem.
The 2023 Point of Care Showcase and Pitch Event will be a free, in-person program beginning at 2 p.m. at Mintz, 1 Financial Center, 40th Floor, Boston, to introduce ...
A team of researchers from EPFL have found a way to use the phenomenon of strong gravitational lensing to determine with precision – about 3 times more precise than any other technique – the mass of a galaxy containing a quasar, as well as their evolution in cosmic time. Knowing the mass of quasar host galaxies provides insight into the evolution of galaxies in the early universe, for building scenarios of galaxy formation and black hole development. The results are published in Nature ...
